Personalized Cystic Fibrosis Therapy and Research Center

个性化囊性纤维化治疗和研究中心

• 批准号: 10672704
• 负责人: Anjaparavanda P Naren
• 金额: $ 21.85万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10672704
• 关键词: Administrative Efficiency; Advisory Committees; Budgets; Clinical Investigator; Collaborations; Core Facility; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dedications; Environment; Fostering; Funding; Goals; Human Resources; Life; Lung; Personal Satisfaction; Principal Investigator; Quality of life; Research; Research Personnel; Services; Shapes; Site; Strategic Planning; clinical care; cystic fibrosis patients; gastrointestinal; implementation facilitation; improved; interest; operation; outreach program; patient outreach; personalized medicine; programs; translational scientist

SUMMARY: The administrative core will promote interaction among researchers and clinicians with interest in CF/CFTR- related research. The implementation of this thematic program, Personalized Medicine in CF, will be its most important goal. Toward this end, the Core will develop a strategic plan; oversee the operations at the Center including budget, core services, the P/F Program, enrichment programs, and membership management. The administration will help shape an excellent research environment for CF/CFTR-related studies by promoting and fostering collaboration between the basic, translational, and clinical investigators. The Administrative Core will provide support to three biomedical cores for their facilities and services and will be proactive in developing patient outreach programs. The ultimate goal is to develop personalized therapy for individuals with CF to improve their quality or life and wellbeing.

概括： 行政核心将促进对CF/CFTR-感兴趣的研究人员和临床医生之间的互动 相关研究。该主题计划的实施，即CF中的个性化医学，将是最大的 重要目标。为此，核心将制定战略计划；监督中心的操作 包括预算，核心服务，P/F计划，丰富计划和会员管理。这 管理将通过促进与CF/CFTR相关研究的出色研究环境 并促进基本，转化和临床研究人员之间的合作。行政核心 将为其设施和服务提供三个生物医学核心的支持，并将积极发展 患者外展计划。最终目标是为患有CF的人开发个性化疗法 改善他们的质量或生活和福祉。